Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 6/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753047 | 0.83 | NR3C2 (0.47) | NR3C2ARCACNA1BAPBA1LMNA | |
| SCHEMBL4530965 | 0.82 | NR3C2 (0.65) | NR3C2TRPV1SCN9ABRD4PLA2G7 | |
| SCHEMBL761147 | 0.81 | NR3C2 (0.70) | NR3C2TRPV1ARBRD4CACNA1B | |
| SCHEMBL754961 | 0.80 | NR3C2 (0.44) | NR3C2ARCACNA1BAPBA1LMNA | |
| SCHEMBL754239 | 0.80 | NR3C2 (0.71) | NR3C2TRPV1ARBRD4CACNA1B | |
| SCHEMBL754877 | 0.80 | NR3C2 (0.63) | NR3C2ARSCN9ABRD4 | |
| SCHEMBL755350 | 0.79 | NR3C2 (0.70) | NR3C2TRPV1ARSCN9ABRD4 | |
| SCHEMBL755189 | 0.79 | NR3C2 (0.70) | NR3C2ARBRD4CACNA1BAPBA1 | |
| SCHEMBL2266367 | 0.78 | NR3C2 (0.67) | NR3C2SCN9ANR3C1BRD4 | |
| SCHEMBL5088338 | 0.77 | NR3C2 (0.67) | NR3C2BRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188073-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-1984345-B9 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | IIJIMA TORU | 2011-10-13 | — | — | US | disclosed |
| EP-1984345-B1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7998956-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | NR3C2, MC2R, NR3C1 | NR3C2 1/4885TRPV1 770/4885AR 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.